Main Menu
Search

21 November 2011

Cambridge Consultants uses medtech expertise to help Sphere Medical achieve public listing

Cambridge Consultants, a leading technology design and development firm, recently completed a comprehensive technical and commercial due diligence programme in support of Sphere Medical Holding plc's listing on the AIM market of the London Stock Exchange.

Sphere Medical is a UK based medical device company, currently completing the development of a range of in vitro diagnostic products designed to provide significant improvements in patient management in a number of hospital specialities. Sphere’s products are expected to allow real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient’s bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision-making to ultimately improve the management of patients.

Cambridge Consultants was selected to perform the technical and commercial due diligence of Sphere Medical due to its extensive experience in the design and development of diagnostic devices and systems, its knowledge of the wider medtech market, and for its track record in providing technical due diligence and consulting services. Cambridge Consultants’ multi-disciplinary team was able to thoroughly analyse Sphere Medical’s technology, from a technical and regulatory standpoint, its commercial prospects, as well as the potential risk factors.

“Cambridge Consultants’ deep understanding of our technology and the markets we are targeting was invaluable in supporting our recent work to achieve an AIM listing,” commented Dr Stuart Hendry, CEO of Sphere Medical. “The approach taken by the Cambridge Consultants team was very thorough and provided a robust and independent Expert’s Report.”

Dr Monika Green, Consulting Director of Cambridge Consultants added: “We worked closely with Sphere Medical to ensure that we fully understood the company, its technology and its business plans. Given our own track record in diagnostic technology we were very pleased to be selected by Sphere Medical to conduct this study. The result of a successful public offering is great news, not only for Sphere Medical but also as validation of the growing medtech sector in Cambridge. To get to this point in the current climate is a significant achievement.”

Notes to editors

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 700 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, oil and gas, and wireless communications.

Cambridge Consultants is part of Altran, a global leader in engineering and R&D services which offers its clients a new way to innovate. Altran works alongside its clients on every link in the value chain of their project, from conception to industrialisation. In 2015, the Altran group generated revenues of €1.945bn. With a headcount of more than 27,000 employees, Altran is present in more than 20 countries. For more information, visit www.altran.com.

Press Contacts

Corporate communications
Debbie Mayhew
PR & Communications Manager
Cambridge Consultants
+44 1223 392418
Debbie.Mayhew@CambridgeConsultants.com

European PR agency
David Vindel
Ketchum
+44 20 3755 6444
CambridgeConsultants@ketchum.com

US PR agency
Hanah Johnson
March Communications
+1 617 960 8892
CambridgeConsultants@ketchum.com